We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Cardiome Delays Phase III Trial to Boost Competitive Position
Cardiome Delays Phase III Trial to Boost Competitive Position
August 18, 2010
Cardiome Pharma is delaying the start of a late-stage trial of its atrial fibrillation drug vernakalant so it can design a Phase III program that will position it to better compete with Sanofi-Aventis’ Multaq (dronedarone HCl).